Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Lfb Biotechnologies

Lfb Sa

Laboratoire Francias Du Franctionnement Et Des Biotechnologies

Michel Nogre

Abdessatar Chtourou

Pierre Porte

Michel Tellier

Roland Schmitthaeusler

Gerald Perret

Damien Bataille

Gérald Perret

Monique Ollivier

Alain Lejars

Abdessatar Sami Chtourou

An anti-Factor VII affinity ligand that is particularly useful for purifying recombinant human activated Factor VII from transgenic sources. The affinity ligand combined with other orthogonal chromatographic steps allows the preparation of a highly purified FVII solution fully activated free of aggregates with a low percentage of degraded or oxidized FVII forms.

Method for purifying transgenic factor VII/VIIA

An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein.

Affinity substrate and methods for selectively purifying a blood plasma protein

Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilized concentrates of said proteins.

Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins

The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing the protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and an ionic characteristic in pH conditions enabling the protein to be retained on the substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluted fraction by removing the milk proteins from the eluted fraction; and e) recovering the protein.

Method for extracting a protein from milk

La present invention pertains to a composition of plasma-derived virally-safe factor VIII, obtained after nanometric filtration, said composition comprising von Willebrand factor (vWF) at a rate of 15% or less of decamers and higher multimers. Such compositions have a reduction factor of the virus titre higher than 4 log and are thus suitable for treatment of hemophilia.

Virally-safe factor VIII with a low content of higher multimers

Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filtering the solution through a hydrophilic virus filter.

Growing community of inventors

Vanves, France

Michel Nogre